268 related articles for article (PubMed ID: 35139070)
1. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
[TBL] [Abstract][Full Text] [Related]
2. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
[TBL] [Abstract][Full Text] [Related]
5. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
[TBL] [Abstract][Full Text] [Related]
7. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
[TBL] [Abstract][Full Text] [Related]
8. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.
Bjerum CM; Ouattara AF; Aboulaye M; Kouadio O; Marius VK; Andersen BJ; Weil GJ; Koudou BG; King CL
Clin Infect Dis; 2020 Oct; 71(7):e68-e75. PubMed ID: 31641754
[TBL] [Abstract][Full Text] [Related]
10. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
King CL; Suamani J; Sanuku N; Cheng YC; Satofan S; Mancuso B; Goss CW; Robinson LJ; Siba PM; Weil GJ; Kazura JW
N Engl J Med; 2018 Nov; 379(19):1801-1810. PubMed ID: 30403937
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
[TBL] [Abstract][Full Text] [Related]
12. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
[TBL] [Abstract][Full Text] [Related]
13. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
[TBL] [Abstract][Full Text] [Related]
14. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
[TBL] [Abstract][Full Text] [Related]
15. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
[TBL] [Abstract][Full Text] [Related]
16. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.
Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
Drug Saf; 2023 Oct; 46(10):961-974. PubMed ID: 37552438
[TBL] [Abstract][Full Text] [Related]
18. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Kura K; Stolk WA; Basáñez MG; Collyer BS; de Vlas SJ; Diggle PJ; Gass K; Graham M; Hollingsworth TD; King JD; Krentel A; Anderson RM; Coffeng LE
Clin Infect Dis; 2024 Apr; 78(Supplement_2):S93-S100. PubMed ID: 38662701
[TBL] [Abstract][Full Text] [Related]
19. Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia.
Supali T; Djuardi Y; ; Sianipar LR; Suryaningtyas NH; Alfian R; Destani Y; Iskandar E; Astuty H; Sugianto N; Fischer PU
Am J Trop Med Hyg; 2024 Jan; 110(1):111-116. PubMed ID: 38011734
[TBL] [Abstract][Full Text] [Related]
20. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
